Endometrial Cancer Clinical Trials

A listing of 104 Endometrial Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Endometrial Cancer

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 104 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264

Recruiting

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/07/2025

Locations: Hoag Memorial Presbyterian, Newport Beach, California +32 locations

Hoag Memorial Presbyterian, Newport Beach, California

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Washington University School of Medicine, Saint Louis, Missouri

Titan Health Partners Llc Dba Astera Cancer Care, East Brunswick, New Jersey

Avera Cancer Institue, Sioux Falls, South Dakota

Mary Crowley Cancer Research, Dallas, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Saint Vincents Hospital Sydney, Darlinghurst, New South Wales

Nepean Hospital, Kingswood, New South Wales

Genesiscare North Shore, St Leonards, New South Wales

Princess Alexandra Hospital, Woolloongabba, Queensland

Cancer Research South Australia, Adelaide, South Australia

Monash Health, Clayton, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing

Beijing Cancer Hospital, Beijing, Beijing

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

Hunan Cancer Hospital, Changsha, Hunan

Shengjing Hospital Affiliated of China Medical University, Shenyang, Liaoning

The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan

Rambam Health Care Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Seoul National University Bundang Hospital, BundangGu SeongnamSi, Gyeonggi-do

National Cancer Center (Korea), IlsandongGu GoyangSi, Gyeonggi-do

Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Asan Medical Center, SongpaGu, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Auckland City Hospital, Auckland, Not set

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer

Learn More ›

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366

Recruiting

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/05/2025

Locations: USOR HonorHealth, Phoenix, Arizona +36 locations

USOR HonorHealth, Phoenix, Arizona

USOR Arizona Oncology Associates, Tucson, Arizona

University of California Los Angeles Medical Center, Los Angeles, California

University of California, San Diego; Moores Cancer Center, San Diego, California

USOR Sansum Clinic, Santa Barbara, California

Providence Medical Foundation, Santa Rosa, California

USOR Florida Cancer Specialists South, Fort Myers, Florida

USOR Florida Cancer Specialists North, Saint Petersburg, Florida

USOR Florida Cancer Specialists East, West Palm Beach, Florida

University of Kansas Medical Center (KUMC), Westwood, Kansas

USOR Maryland Oncology Hematology, Rockville, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

START Midwest, Grand Rapids, Michigan

USOR Minnesota Oncology Hematology, Maplewood, Minnesota

University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

USOR Oncology Associates of Oregon, P.C., Eugene, Oregon

Compass Oncology - Rose Quarter, Portland, Oregon

USOR Alliance Cancer Specialist, Doylestown, Pennsylvania

Women and Infants Hospital of Rhode Island, Providence, Rhode Island

Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee

USOR Texas Oncology, Abilene, Texas

Texas Oncology - Central / South Texas, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

USOR Texas Oncology, Fort Worth, Texas

Texas Oncology - Northeast TX, Tyler, Texas

USOR Texas Oncology Gulf Coast, Woodland, Texas

START Mountain Region, West Valley City, Utah

USOR Virginia Cancer Specialists, Fairfax, Virginia

USOR Virginia Oncology Associates, Norfolk, Virginia

Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing

Hunan Cancer Hospital - Phase 1, Changsha, Hunan

Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan

Jilin Cancer Hospital, Chang chun, Jilin

Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai, Shanghai

Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai

Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Platinum-resistant Ovarian Cancer (PROC), Primary Refractory Ovarian Cancer, Uterine Cancer

Learn More ›

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845

Recruiting

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/05/2025

Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +17 locations

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression

Learn More ›

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Recruiting

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.

Gender:

ALL

Ages:

12 years and above

Trial Updated:

05/05/2025

Locations: Hoag Cancer Center, Irvine, California +73 locations

Hoag Cancer Center, Irvine, California

University of California Irvine Chao Family Comprehensive Cancer Center, Irvine, California

UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

University of San Francisco, San Francisco, California

Rocky Mountain Cancer Center, Denver, Colorado

Yale Cancer Center, New Haven, Connecticut

Medical Oncology Hematology Consultants, Newark, Delaware

University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida

Florida Cancer Specialists South, Port Charlotte, Florida

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

New York University, New York, New York

Memorial Sloan Kettering, New York, New York

Duke University, Durham, North Carolina

The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

University of Oklahoma, Oklahoma City, Oklahoma

Oregon Health & Science University (OHSU), Portland, Oregon

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Sarah Cannon Research Institute, Nashville, Tennessee

Vanderbilt University Medical Center - Ingram Cancer Center, Nashville, Tennessee

New Experimental Therapeutics - NEXT Oncology, Austin, Texas

UT Southwest Simmons Cancer Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio, Texas

Virginia Cancer Specialists, Fairfax, Virginia

University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Chris O'Brien Lifehouse Hospital, Camperdown, New South Wales

Mater Cancer Care Centre, South Brisbane, Queensland

Flinders Medical Center, Bedford Park, South Australia

Monash Medical Centre, Clayton, Victoria

Linear Clinical Research, Nedlands, Western Australia

ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg, Bas-Rhin

Institut Bergonie, Bordeaux, Gironde

Institut Claudius Regaud, Toulouse, Haute-Garonne

EDOG Institut de Cancerologie de l'Ouest, Saint-Herblain, Loire-Atlantique

Centre Jean Perrin, Clermont-Ferrand, Puy-de-Dôme

Institut Gustave Roussy, Villejuif, Val-de-Marne

Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer, Lyon, Not set

CHU de Nîmes, Nîmes, Not set

Institute Cancer De Lorraine, Vandœuvre-lès-Nancy, Not set

Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg, Baden-Württemberg

Universitätsklinikum Augsburg, Augsburg, Bayern

Universitätsklinikum Frankfurt, Frankfurt, Hessen

Universitätsklinikum Essen, Essen, Nordrhein-Westfalen

Asklepios Klinik Altona, Hamburg, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio

Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena, Rome, Lazio

ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia

Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Lombardia

Istituto Europeo Di Oncologia, Milano, Lombardia

Istituto Clinico Humanitas, Rozzano, Lombardia

Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Torino

IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale, Napoli, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul University Hospital, Seoul, Not set

Severance Hospital Yonsei University, Seoul, Not set

National University Hospital, Kent Ridge, Not set

National Cancer Center of Singapore, Singapore, Not set

Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON, Barcelona, Not set

NEXT Oncology-Hospital Quironsalud Barcelona, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

START MADRID_Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

START MADRID_Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sarah Cannon Research Institute UK, London, Middlesex

Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear

Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer

Learn More ›

PRO1107 in Patients With Advanced Solid Tumors

NCT06171789

Recruiting

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/05/2025

Locations: HonorHealth Research Institute, Scottsdale, Arizona +5 locations

Conditions: Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma

Learn More ›

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441

Recruiting

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +152 locations

University of Arkansas for Medical Sciences, Little Rock, Arkansas

City of Hope, Duarte, California

UC San Diego Medical Center, La Jolla, California

Stanford Women's Cancer Center, Palo Alto, California

Kaiser Permanente Medical Center, Vallejo, California

University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado

Yale University School of Medicine, New Haven, Connecticut

Florida Cancer Specialists, Fort Myers, Florida

University of Florida, Gainesville, Florida

Tampa General Hospital (Cancer Institute), Tampa, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

Lewis Cancer & Research Pavilion at St. Joseph's/Candler Health System, Savannah, Georgia

University of Chicago Medical Center, Chicago, Illinois

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

Baptist Health Lexington, Lexington, Kentucky

Norton Cancer Institute, Louisville, Kentucky

Women's Cancer Care, Covington, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Greater Baltimore Medical Center, Baltimore, Maryland

Tufts Medical Center, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Baystate Medical Center, Springfield, Massachusetts

West Michigan Cancer Center, Kalamazoo, Michigan

M Health Fairview University of Minnesota Medical Center - East Bank Hospital, Minneapolis, Minnesota

Metro Minnesota Community Oncology Research Consortium (MMCORC), Saint Louis Park, Minnesota

Rutgers Cancer Institute, New Brunswick, New Jersey

University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico

Roswell Park Cancer Institute, Buffalo, New York

Northwell Health Cancer Institute, Lake Success, New York

Memorial Sloan Kettering Cancer Center, New York, New York

SUNY Upstate Medical University, Syracuse, New York

Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina

Cleveland Clinic, Cleveland, Ohio

Ohio Health Research Institute, Columbus, Ohio

Oklahoma Cancer Specialists and Research Institute - OCSRI - Tulsa, Tulsa, Oklahoma

Providence Cancer Institute Franz Clinic, Portland, Oregon

Alliance Cancer Specialists, PC, Horsham, Pennsylvania

University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

SCRI Oncology Partners, Nashville, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

Texas Oncology, Fort Worth, Texas

Baylor College of Medicine Medical Center, Houston, Texas

University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia

Virginia Oncology Associates, Norfolk, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Froedtert and the Medical College of Wisconsin (MCW), Milwaukee, Wisconsin

Chris O'Brien Lifehouse, Camperdown, New South Wales

Monash Health, Clayton, Victoria

Peter MacCallum Cancer Centre, Melbourne, Victoria

Clínica de Neoplasias Litoral, Itajai, Not set

McGill University Health Centre - Glen Site, Montreal, Not set

CIC-CHU de Québec-Université Laval- Hôpital de l'Enfant-Jésus, Quebec, Not set

Sunnybrook Research Institute, Toronto, Not set

Beijing Cancer Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun, Not set

Hunan Cancer Hospital, Changsha, Not set

West China Second Hospital of Sichuan University, Chengdu, Not set

Chongqing University Cancer Hospital, Chongqing, Not set

Guangxi Medical University Affiliated Tumor Hospital, Guangxi Zhuang Autonomous Region, Not set

Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Not set

Women's Hospital School Of Medicine Zhejiang University, Hangzhou, Not set

Zhejiang Cancer Hospital, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Jiangxi Maternal and Child Health Hospital, Nanchang, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Shanghai Tenth People's Hospital, Shanghai, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Not set

Tongji Hospital, Tongji Medical College of HUST, Wuhan, Not set

The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Nemocnice AGEL, Nový Jičín a.s., Nový Jičín, Not set

General University Hospital in Prague, Prague, Not set

University Hospital Bulovka, Prague, Not set

Centre Francois Baclesse, Caen Cedex 5, Not set

Institut Paoli Calmettes, Marseille, Not set

Centre Antoine Lacassagne, Nice, Not set

Hôpital Cochin, Paris, Not set

HCL - Centre Hospitalier Lyon Sud, Pierre Benite, Not set

ICO - Centre René Gauducheau, Saint-Herblain, Not set

Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, Not set

Institut Gustave Roussy, Villejuif, Not set

Hochtaunus Kliniken Bad Homburg, Bad Homburg, Not set

University Hospital Essen, Essen, Not set

Universitätsklinikum Hamburg, Hamburg, Not set

Medical School Hannover, Hannover, Not set

University Hospital Leipzig, Leipzig, Not set

Klinikum rechts der Isar der TU München, Klinik und Poliklinik für Frauenheilkunde, München, Not set

Universitätsklinikum Ulm, Ulm, Not set

Aretaeion Hospital, Athens, Not set

General Hospital of Patras Agios Andreas, Patras, Not set

St. Luke's Hospital, Thessaloniki, Not set

Hong Kong Sanatorium & Hospital, Happy Valley, Not set

Queen Mary Hospital, Hong Kong, Not set

Prince of Wales Hospital, New Territories, Not set

Hillel Yaffe Medical Center, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Wolfson Medical Center, Holon, Not set

Hadassah Medical Center, Jerusalem, Not set

Sheba Medical Center, ramat GAn, Not set

Sourasky T.A.M.C., Tel Aviv-Yaffo, Not set

SOC di Oncologia Medica e Prevenzione Oncologica Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Not set

Azienda Ospedaliera Universitaria Careggi - Unita di Oncologia Ginecologica, Firenze, Not set

ASST Lecco - Ospedale Alessandro Manzoni, Lecco, Not set

Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST, Meldola, Not set

Irccs Ospedale San Raffaele-UO Ginecologia, Milan, Not set

Istituto Europeo di Oncologia, Milan, Not set

Azienda Ospedaliero Universitaria Pisana, Ospedale Santa Chiara, Pisa, Not set

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Not set

Istituto Nazionale Tumori Regina Elena IRCCS, Rome, Not set

A.O. Ordine Mauriziano di Torino, Torino, Not set

Chiba Cancer Center, Chiba, Not set

The Jikei University Kashiwa Hospital, Chiba, Not set

Hyogo Cancer Center, Hyogo, Not set

St. Marianna University Hospital, Kanagawa, Not set

Mie University Hospital, Mie, Not set

Okayama University Hospital, Okayama, Not set

Saitama Medical University International Medical Center, Saitama, Not set

Shizuoka Cancer Center, Shizuoka, Not set

National Cancer Center Hospital, Tokyo, Not set

The Cancer Institute Hospital Of JFCR, Tokyo, Not set

Keimyung University Dongsan Medical Center, Dalseo-gu, Not set

National Cancer Center - Korea, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Severance Hospital, Seoul, Not set

Szpitale Pomorskie Sp. z o.o., Gdynia, Not set

Uniwersyteckie Centrum Kliniczne SUM, Katowice, Not set

Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach, Siedlce, Not set

National University Hospital, Singapore, Not set

Complexo Hospitalario Universitario A Coruna, A Coruña, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitario Ciudad de Jaen, Jaén, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Universitario Clinico San Carlos, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Hospital Universitari Son Espases, Palma, Not set

Hospital Parc Taulí, Sabadell, Not set

Hospital Universitario La Fe - Valencia, Valencia, Not set

Kaohsiung Veterans General Hospital, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Mackay Memorial Hospital, Taipei, Not set

Chang Gung Memorial Hospital, Linkou, Taoyuan City, Not set

Cambridge University Hospitals NHS Foundation Trust, Cambridge, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

University Hospitals of Leicester NHS Trust-Leicester Royal Infirmary, Leicester, Not set

University College London Hospitals, London, Not set

East and North Hertfordshire NHS Trust - Mount Vernon Cancer Centre, Northwood, Not set

Conditions: Endometrial Cancer

Learn More ›

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

NCT02628067

Recruiting

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: Call for Information (Investigational Site 0008), New Brunswick, New Jersey +18 locations

Conditions: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma

Learn More ›

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958

Recruiting

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who r... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/30/2025

Locations: USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama +239 locations

USA Mitchell Cancer Institute ( Site 4142), Mobile, Alabama

Alaska Womens Cancer Care ( Site 4122), Anchorage, Alaska

HonorHealth (HH) ( Site 8000), Phoenix, Arizona

Arizona Oncology Associates - HOPE ( Site 8002), Tucson, Arizona

UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc, Los Angeles, California

California Pacific Medical Center - Van Ness Campus ( Site 4129), San Francisco, California

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114), New Haven, Connecticut

MedStar Washington Hospital Center ( Site 4108), Washington, District of Columbia

Mount Sinai Cancer Center ( Site 4117), Miami Beach, Florida

AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113), Orlando, Florida

Florida Cancer Specialists - East ( Site 7000), West Palm Beach, Florida

Northside Hospital ( Site 4112), Atlanta, Georgia

Augusta University ( Site 4116), Augusta, Georgia

Centricity Research Columbus Cancer Center ( Site 4154), Columbus, Georgia

NorthShore University HealthSystem - Evanston Hospital ( Site 4110), Evanston, Illinois

Parkview Research Center at Parkview Regional Medical Center ( Site 4132), Fort Wayne, Indiana

Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 4150), Edgewood, Kentucky

University Medical Center New Orleans ( Site 4133), New Orleans, Louisiana

TRIALS 365 ( Site 4105), Shreveport, Louisiana

University of Massachusetts Memorial Medical Center ( Site 4103), Worcester, Massachusetts

Washington University School of Medicine-Obstetrics & Gynecology ( Site 4146), Saint Louis, Missouri

The Center of Hope ( Site 4109), Reno, Nevada

John Theurer Cancer Center at Hackensack University Medical Center ( Site 4118), Hackensack, New Jersey

Atlantic Health System Morristown Medical Center ( Site 4135), Morristown, New Jersey

Holy Name Medical Center ( Site 4115), Teaneck, New Jersey

New York - Presbyterian Brooklyn Methodist Hospital ( Site 4134), Brooklyn, New York

Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 4156), Mineola, New York

Laura and Isaac Perlmutter Cancer Center ( Site 4106), New York, New York

Icahn School of Medicine at Mount Sinai-Department of Obstetrics, Gynecology, and Reproductive Scie, New York, New York

Good Samaritan Hospital Medical Center ( Site 4139), West Islip, New York

Duke Cancer Institute ( Site 4120), Durham, North Carolina

Sanford Health Roger Maris Cancer Center ( Site 4158), Fargo, North Dakota

University of Cincinnati Medical Center ( Site 4136), Cincinnati, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Sidney Kimmel Cancer Center - Jefferson Health ( Site 4157), Philadelphia, Pennsylvania

AHN West Penn Hospital-Gynecologic Oncology ( Site 4111), Pittsburgh, Pennsylvania

Asplundh Cancer Pavilion ( Site 4107), Willow Grove, Pennsylvania

Women & Infants Hospital ( Site 4138), Providence, Rhode Island

Sanford Cancer Center-Gynecologic Oncology ( Site 4121), Sioux Falls, South Dakota

The West Clinic, PLLC dba West Cancer Center ( Site 4102), Germantown, Tennessee

Houston Methodist Hospital-Obstetrics and Gynecology ( Site 4130), Houston, Texas

Texas Oncology - San Antonio ( Site 8005), San Antonio, Texas

Texas Oncology - Gulf Coast ( Site 8006), The Woodlands, Texas

Hospital Británico de Buenos Aires-Oncology ( Site 1002), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto Argentino de Diagnóstico y Tratamiento (IADT) ( Site 1008), Buenos Aires, Caba

Instituto Alexander Fleming-Alexander Fleming ( Site 1007), Ciudad Autónoma de Buenos Aires, Caba

Hospital Aleman-Oncology ( Site 1001), Buenos Aires, Not set

Instituto de Oncología Angel H. Roffo ( Site 1003), Buenos Aires, Not set

Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1004), Buenos Aires, Not set

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 1006), La Rioja, Not set

GenesisCare North Shore ( Site 1103), St Leonards, New South Wales

Blacktown Hospital ( Site 1101), Sydney, New South Wales

Royal Brisbane and Women's Hospital ( Site 1102), Brisbane, Queensland

Epworth Freemasons ( Site 1104), East Melbourne, Victoria

Frankston Hospital ( Site 1105), Frankston, Victoria

Medizinische Universitaet Innsbruck-Univ.-Klinik f. Gynäkologie und Geburtshilfe ( Site 1201), Innsbruck, Tirol

Medizinische Universität Wien ( Site 1202), Wien, Not set

AZ Maria Middelares-IKG ( Site 1305), Gent, Oost-Vlaanderen

UZ Gent-Medical oncology ( Site 1303), Gent, Oost-Vlaanderen

UZ Leuven-Gynecologic Oncology ( Site 1301), Leuven, Vlaams-Brabant

AZ Delta vzw-Oncology ( Site 1302), Roeselare, West-Vlaanderen

CHU UCL Namur/Site Sainte Elisabeth-Trial Office ( Site 1304), Namur, Not set

Hospital São Domingos ( Site 1365), Sao Luis, Maranhao

Centro Oncologico do Triangulo ( Site 1360), Uberlândia, Minas Gerais

Hospital Moinhos de Vento ( Site 1359), Porto Alegre, Rio Grande Do Sul

Instituto Joinvilense de Hematologia e Oncologia ( Site 1353), Joinville, Santa Catarina

Instituto de Ensino e Pesquisa ( Site 1355), Sorocaba, Sao Paulo

Instituto de Educação, Pesquisa e Gestão em Saúde ( Site 1352), Rio de Janeiro, Not set

Hospital Samaritano De Sao Paulo ( Site 1367), Sao Paulo, Not set

A. C. Camargo Cancer Center ( Site 1351), Sao Paulo, Not set

IBCC - Núcleo de Pesquisa e Ensino ( Site 1366), Sao Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre ( Site 1413), Calgary, Alberta

Cross Cancer Institute ( Site 1414), Edmonton, Alberta

BC Cancer Vancouver ( Site 1415), Vancouver, British Columbia

Trillium Health Partners - Credit Valley Hospital ( Site 1410), Mississauga, Ontario

CIUSSS- saguenay-Lac-Saint-Jean ( Site 1408), Chicoutimi, Quebec

CIUSSS de l'Est-de-l'Île-de-Montréal ( Site 1405), Montreal, Quebec

Centre Hospitalier de l'Université de Montréal ( Site 1403), Montréal, Quebec

McGill University Health Centre ( Site 1404), Montréal, Quebec

James Lind Centro de Investigacion del Cancer ( Site 1504), Temuco, Araucania

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1505), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 1503), Santiago, Region M. De Santiago

Bradfordhill-Clinical Area ( Site 1501), Santiago, Region M. De Santiago

Second Affiliated hospital of Anhui Medical University-Oncology ( Site 1635), Hefei, Anhui

Beijing Obstetric and Gynecology Hospital ( Site 1653), Beijing, Beijing

Fujian Cancer Hospital-Gynecological Oncology Surgery ( Site 1627), Fuzhou, Fujian

The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 1613), Xiamen, Fujian

Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1634), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1604), Guangzhou, Guangdong

Cancer Hospital of Shantou University Medical College ( Site 1642), Shantou, Guangdong

Affiliated Hospital of Guangdong Medical University ( Site 1614), Zhanjiang, Guangdong

Guangxi Medical University Affiliated Tumor Hospital-Gynecological oncology ( Site 1622), Nanning, Guangxi

Hainan General Hospital ( Site 1636), Haikou, Hainan

Harbin Medical University Cancer Hospital-Gynecological Radiotherapy Department ( Site 1652), Harbin, Heilongjiang

Henan Cancer Hospital ( Site 1618), Zhengzhou, Henan

The Second Affiliated Hospital of Zhengzhou University ( Site 1640), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1621), Wuhan, Hubei

Hubei Cancer Hospital-Hubei Cancer Hospital ( Site 1607), Wuhan, Hubei

Xiangya Hospital Central South University-Gynecology ( Site 1603), Changsha, Hunan

Hunan Cancer Hospital ( Site 1623), Changsha, Hunan

Nanjing First Hospital ( Site 1649), Nanjing, Jiangsu

Jiangxi Maternal and Child Health Hospital-Oncology Department ( Site 1625), Nanchang, Jiangxi

LinYi Cancer Hospital-Gastrology department ( Site 1630), Linyi, Shandong

Obstetrics & Gynecology Hospital of Fudan University ( Site 1617), Shanghai, Shanghai

Shanghai First Maternity and Infant Hospital-Gynecology department ( Site 1626), Shanghai, Shanghai

West China Second University Hospital, Sichuan University ( Site 1602), Chengdu, Sichuan

Sichuan Cancer hospital-Oncology ( Site 1650), Chengdu, Sichuan

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 1648), Urumqi, Xinjiang

Yunnan Province Cancer Hospital-Gynecology Department ( Site 1641), Kunming, Yunnan

The Affiliated Women's Hospital of Zhejiang University-Obstetrics and Gynecology ( Site 1609), Hangzhou, Zhejiang

Zhejiang Cancer Hospital-Oncology ( Site 1601), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 1633), Linhai, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University ( Site 1615), Wenzhou, Zhejiang

Fakultní Nemocnice Brno-Gynekologicko-porodnicka klinika ( Site 1704), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Gynekologicko-porodnicka klinika ( Site 1703), Ostrava, Moravskoslezsky Kraj

Nemocnice AGEL Novy Jicin a.s.-Oddeleni radioterapie a onkologie ( Site 1706), Nový Jiín, Novy Jicin

Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1702), Olomouc, Olomoucky Kraj

Fakultni nemocnice Kralovske Vinohrady ( Site 1707), Praha, Praha 10

Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1705), Praha, Praha 2

Fakultni nemocnice Bulovka-Gynekologicko-porodnicka klinika ( Site 1701), Praha, Praha 8

Herlev and Gentofte Hospital-Department of Oncology ( Site 1801), Copenhagen, Hovedstaden

Rigshospitalet-Dept. of Oncology ( Site 1803), Copenhagen, Hovedstaden

Aarhus Universitetshospital, Skejby ( Site 1802), Aarhus, Midtjylland

Tampereen yliopistollinen sairaala ( Site 1901), Tampere, Pirkanmaa

Kuopion Yliopistollinen Sairaala ( Site 1904), Kuopio, Pohjois-Savo

Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) ( Site 1902), Helsinki, Uusimaa

Turku University Hospital-Department of Obstetrics and Gynecology ( Site 1903), Turku, Varsinais-Suomi

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest ( Site 2002), Bordeaux, Aquitaine

ROC37 ( Site 2010), Chambray Les Tours, Centre

Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 2001), Plerin, Cotes-d Armor

CHU Besançon ( Site 2009), Besançon, Doubs

Institut Claudius Regaud ( Site 2006), Toulouse, Haute-Garonne

Institut Regional du Cancer Montpellier ( Site 2008), Montpellier, Herault

Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 2003), Rennes, Ille-et-Vilaine

Centre Oscar Lambret ( Site 2007), Lille, Nord-Pas-de-Calais

CENTRE LEON BERARD ( Site 2004), Lyon Cedex08, Rhone-Alpes

Groupe Hospitalier Diaconesses Croix Saint Simon ( Site 2005), Paris, Not set

SLK-Kliniken Heilbronn ( Site 2107), Heilbronn, Baden-Wurttemberg

Universitätsmedizin Mannheim-Department of Obstetrics and Gynecology ( Site 2101), Mannheim, Baden-Wurttemberg

MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum ( Site 2110), Ravensburg, Baden-Wurttemberg

Universitaetsklinikum Tuebingen ( Site 2111), Tübingen, Baden-Wurttemberg

Klinikum der Universität München Großhadern-Klinik und Poliklinik für Frauenheilkunde und Geburtshi, Munich, Bayern

Charité Campus Virchow-Klinikum ( Site 2102), Berlin, Not set

Agios Andreas Hospital Patras ( Site 2201), Patras, Achaia

Aretaieio Hospital Oncology Unit ( Site 2206), Athens, Attiki

Metropolitan Hospital-2nd Oncology Dept ( Site 2202), Athens, Attiki

Hygeia Hospital ( Site 2204), Marousi, Attiki

Cork University Hospital ( Site 2402), Cork, Not set

Mater Misericordiae University Hospital ( Site 2403), Dublin, Not set

St. James's Hospital-Cancer clinical trials office ( Site 2401), Dublin, Not set

Rambam Health Care Campus-Gyneco-oncology unit ( Site 2502), Haifa, Not set

Edith Wolfson Medical Center ( Site 2501), Holon, Not set

Shaare Zedek Medical Center ( Site 2503), Jerusalem, Not set

Rabin Medical Center ( Site 2505), Petah Tikva, Not set

Sheba Medical Center ( Site 2504), Ramat Gan, Not set

Sourasky Medical Center ( Site 2506), Tel Aviv, Not set

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlin-SSD Oncologia medica Addarii ( Site 260, Bologna, Emilia-Romagna

CRO-IRCCS ( Site 2609), Aviano, Friuli-Venezia Giulia

AOU Policlinico Umberto I ( Site 2606), Roma, Lazio

Istituto Europeo di Oncologia IRCCS ( Site 2607), Milano, Lombardia

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Chirurgia Ginecologica ( Site 260, Milan, Lombardia

Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 2610), Rozzano, Milano

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'O-Day Hospital Oncologico Multidisciplin, Candiolo, Torino

Instituto Tumori Giovanni Paolo II-ONCOLOGIA MEDICA ( Site 2604), Bari, Not set

Azienda Ospedaliera Spedali Civili di Brescia-Obstetrics anf gynecology ( Site 2611), Brescia, Not set

Humanitas San Pio X Hospital ( Site 2614), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Oncologia Sperimentale Uro-Genitale ( Site 2, Napoli, Not set

Arcispedale Santa Maria Nuova ( Site 2612), Reggio Emilia, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2601), Roma, Not set

Ospedale Mauriziano-Ginecologia e Ostetricia ( Site 2608), Torino, Not set

Aichi Cancer Center Hospital ( Site 2714), Nagoya, Aichi

National Hospital Organization Shikoku Cancer Center ( Site 2705), Matsuyama, Ehime

Ehime University Hospital ( Site 2709), Toon, Ehime

Kurume University Hospital ( Site 2703), Kurume, Fukuoka

Gunma Prefectural Cancer Center ( Site 2708), Otashi, Gunma

Hokkaido University Hospital ( Site 2707), Sapporo, Hokkaido

University of Tsukuba Hospital ( Site 2713), Tsukuba, Ibaraki

Iwate Medical University Hospital ( Site 2712), Shiwa-gun, Iwate

Niigata Cancer Center Hospital ( Site 2701), Niigata-shi, Niigata

Saitama Medical University International Medical Center ( Site 2710), Hidaka, Saitama

Shizuoka Cancer Center ( Site 2716), Sunto-gun,, Shizuoka

National Cancer Center Hospital ( Site 2715), Chuo-ku, Tokyo

Cancer Institute Hospital of JFCR ( Site 2706), Koto, Tokyo

Showa Medical University Hospital ( Site 2719), Shinagawa, Tokyo

Keio University Hospital ( Site 2702), Shinjuku, Tokyo

National Hospital Organization Kyushu Cancer Center ( Site 2711), Fukuoka, Not set

Kagoshima City Hospital ( Site 2717), Kagoshima, Not set

Osaka International Cancer Institute ( Site 2718), Osaka, Not set

Seoul National University Bundang Hospital-Obstetrics and Gynecology ( Site 3505), Seongnam, Kyonggi-do

Seoul National University Hospital ( Site 3502), Seoul, Not set

Severance Hospital, Yonsei University Health System-Gynecologic cancer center ( Site 3503), Seoul, Not set

Asan Medical Center-Division of Gynecologic Oncology, Dept. of Obstetrics & Gynecology ( Site 3501), Seoul, Not set

Samsung Medical Center ( Site 3504), Seoul, Not set

Pantai Hospital Kuala Lumpur-Cancer Centre ( Site 2803), Kuala Lumpur, Not set

University Malaya Medical Centre ( Site 2801), Kuala Lumpur, Not set

COI Centro Oncologico Internacional S.A.P.I. de C.V. ( Site 2902), Coyoacan, Distrito Federal

Higiea Oncologia ( Site 2905), Mexico City, Distrito Federal

CENTRO MEDICO ZAMBRANO HELLION-Centro de Cáncer de Mama ( Site 2901), San Pedro Garza Garcia, Nuevo Leon

Oncare - Unidad Valle ( Site 2906), San Pedro Garza García, Nuevo Leon

Centro de Investigacion Clinica de Oaxaca ( Site 2907), Oaxaca de Juarez, Oaxaca

Radboudumc-Medical Oncology ( Site 3003), Nijmegen, Gelderland

Amsterdam UMC - locatie VUmc ( Site 3004), Amsterdam, Noord-Holland

Leids Universitair Medisch Centrum-Medical Oncology ( Site 3002), Leiden, Zuid-Holland

Stavanger Universitetssykehus ( Site 3103), Stavanger, Rogaland

Universitetssykehuset Nord-Norge HF ( Site 3101), Tromsø, Troms

Sorlandet Sykehus Kristiansand ( Site 3104), Kristiansand, Vest-Agder

Oslo universitetssykehus, Radiumhospitalet ( Site 3102), Oslo, Not set

Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 3201), Siedlce, Mazowieckie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Ginekologii Onkologicznej ( Sit, Warszawa, Mazowieckie

Bialostockie Centrum Onkologii-Oddzial Onkologii Ginekologicznej ( Site 3204), Bialystok, Podlaskie

Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie-Oddział Radioterapii i Onkologii Ginek, Poznan, Wielkopolskie

Ad-Vance Medical Research-Research ( Site 3302), Ponce, Not set

Pan American Center for Oncology Trials - Ciudadela ( Site 3301), San Juan, Not set

UPR Comprehensive Cancer Center-Comprehensive Cancer Center Hospital ( Site 3304), San Juan, Not set

National Cancer Centre Singapore-Medical Oncology ( Site 3401), Singapore, Central Singapore

Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 3608), L Hospitalet, Barcelona

Institut Català d'Oncologia (ICO) - Girona-Oncología Médica ( Site 3606), Girona, Gerona

Clinica Universidad de Navarra ( Site 3603), Madrid, Madrid, Comunidad De

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 3607), Madrid, Madrid, Comunidad De

Hospital Universitario La Paz-Oncología Médica ( Site 3604), Madrid, Madrid, Comunidad De

Fundación Instituto Valenciano de Oncología-Oncologico ( Site 3605), Valencia, Valenciana, Comunitat

HOSPITAL CLINICO DE VALENCIA ( Site 3609), Valencia, Valenciana, Comunitat

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 3602), Barcelona, Not set

Hospital Universitario Reina Sofia-Oncologia Medica ( Site 3601), Cordoba, Not set

Skånes Universitetssjukhus Lund ( Site 3702), Lund, Skane Lan

Karolinska Universitetssjukhuset Solna ( Site 3701), Stockholm, Stockholms Lan

University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 3808), Basel, Basel-Stadt

Kantonsspital Graubünden-Medizin ( Site 3803), Chur, Grisons

Ospedale Regionale Bellinzona e Valli ( Site 3802), Bellinzona, Ticino

Inselspital Bern-Oncology ( Site 3801), Berne, Not set

University Hospitals Sussex NHS Foundation Trust ( Site 4006), East Sussex, Brighton And Hove

Royal Derby Hospital ( Site 4007), Derby, Derbyshire

ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre ( Site 4002), London, England

The Royal Cornwall Hospital ( Site 4009), Truro, England

University College London Hospital-Cancer Clinical Trials Unit ( Site 4004), London, London, City Of

Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 4008), London, London, City Of

Hammersmith Hospital ( Site 4001), London, London, City Of

The Beatson West of Scotland Cancer Centre ( Site 4005), Glasgow, Scotland

Royal Marsden Hospital (Sutton)-Gynaecology Unit ( Site 4010), London, Sutton

The Christie NHS Foundation Trust-Medical Oncology ( Site 4003), Manchester, Not set

Conditions: Endometrial Cancer

Learn More ›

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

NCT05559879

Recruiting

Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing. Pre-clinical evidence supports the combination of using Vascular Endothelial Growth Factors (VEGF) inhibitors with immunotherapy. VEGF inhibitors suppress the activation of tumor-associated macrophages (TAMs) and VEGF has been shown to affect the functional maturation of dendritic cells; therefore, VEGF inhibitors could improve the function of a... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

04/30/2025

Locations: O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer

Learn More ›

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT03682289

Recruiting

This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/29/2025

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +2 locations

Conditions: Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer

Learn More ›

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06239194

Recruiting

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Sarah Cannon Research Institute, Denver, Colorado +4 locations

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer

Learn More ›

Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer

NCT05850663

Recruiting

The purpose of this study is to examine the uses of a mobile health-based assessment and symptom monitoring platform.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma

Conditions: Head and Neck Cancer, Gynecologic Cancer, Cervical Cancer, Endometrial Cancer

Learn More ›

1 - 12 of 104